Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): two randomized, double-blind, placebo-controlled, phase 3 trials
Capsule Summary: Dupilumab significantly reduced urticaria activity in patients with CSU who were symptomatic despite H1-AH; with a trend towards improvement in patients with prior anti-IgE treatment. Safety was consistent with the known dupilumab safety profile.